HIGHLIGHTS
- who: . and colleagues from the Cancer Center, University of Kansas, United States have published the paper: TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure, in the Journal: (JOURNAL)
- what: This work attempted to compare the efficacy and safety of TKI monotherapy and TKI in combination with PD-1 inhibitors in HCC patients after sorafenib failure. Fourth, this studies on second-line therapy choices for HCC patients are all conducted with sorafenib as a first-line treatment.
SUMMARY
Even though the use . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.